ECSP20075198A - Anticuerpos anti-cd33, anticuerpos biespecíficos anti-cd33/anti-cd3 y usos de estos - Google Patents

Anticuerpos anti-cd33, anticuerpos biespecíficos anti-cd33/anti-cd3 y usos de estos

Info

Publication number
ECSP20075198A
ECSP20075198A ECSENADI202075198A ECDI202075198A ECSP20075198A EC SP20075198 A ECSP20075198 A EC SP20075198A EC SENADI202075198 A ECSENADI202075198 A EC SENADI202075198A EC DI202075198 A ECDI202075198 A EC DI202075198A EC SP20075198 A ECSP20075198 A EC SP20075198A
Authority
EC
Ecuador
Prior art keywords
antibodies
antigen
methods
binding fragments
specific antibodies
Prior art date
Application number
ECSENADI202075198A
Other languages
English (en)
Inventor
Michael Diem
Móvil S A B De C V América
Priyanka Nair-Gupta
Francois Gaudet
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of ECSP20075198A publication Critical patent/ECSP20075198A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se describen anticuerpos anti-CD33 y fragmentos de unión al antígeno de estos y anticuerpos biespecíficos anti-CD33/anti-CD3 o fragmentos de unión al antígeno de estos. También se describen ácidos nucleicos que codifican los anticuerpos, composiciones que comprenden los anticuerpos, métodos para producir los anticuerpos y métodos para usar los anticuerpos para tratar o prevenir enfermedades, tales como el cáncer.
ECSENADI202075198A 2018-05-24 2020-11-23 Anticuerpos anti-cd33, anticuerpos biespecíficos anti-cd33/anti-cd3 y usos de estos ECSP20075198A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862676123P 2018-05-24 2018-05-24
US201962825846P 2019-03-29 2019-03-29

Publications (1)

Publication Number Publication Date
ECSP20075198A true ECSP20075198A (es) 2020-12-31

Family

ID=67211770

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202075198A ECSP20075198A (es) 2018-05-24 2020-11-23 Anticuerpos anti-cd33, anticuerpos biespecíficos anti-cd33/anti-cd3 y usos de estos

Country Status (23)

Country Link
US (1) US11466082B2 (es)
EP (1) EP3802606A2 (es)
JP (1) JP2021524244A (es)
KR (1) KR20210013156A (es)
CN (1) CN112189022A (es)
AU (1) AU2019274229A1 (es)
BR (1) BR112020023357A2 (es)
CA (1) CA3101270A1 (es)
CL (1) CL2020003028A1 (es)
CO (1) CO2020014575A2 (es)
CR (1) CR20200567A (es)
EC (1) ECSP20075198A (es)
IL (1) IL278844A (es)
JO (1) JOP20190116A1 (es)
MA (1) MA52771A (es)
MX (1) MX2020012588A (es)
NI (1) NI202000088A (es)
PE (1) PE20210180A1 (es)
PH (1) PH12020552010A1 (es)
SG (1) SG11202011210TA (es)
TW (1) TW202033551A (es)
UY (1) UY38242A (es)
WO (1) WO2019224711A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108289949B (zh) 2015-05-29 2022-04-12 安普希韦纳治疗公司 双特异性cd33和cd3结合蛋白质的使用方法
MX2020012587A (es) 2018-05-24 2021-04-28 Janssen Biotech Inc Anticuerpos anti-cd3 y usos de estos.
DE102018127845A1 (de) 2018-11-07 2020-05-07 Grimme Landmaschinenfabrik Gmbh & Co. Kg Verfahren zur Regelung des Betriebs einer Maschine zum Ernten von Hackfrüchten
JP2022523188A (ja) * 2019-02-22 2022-04-21 メモリアル スローン ケタリング キャンサー センター Ｃｄ３３抗体とそれを用いた癌を治療する方法
IL293670A (en) * 2019-12-09 2022-08-01 Twist Bioscience Corp Variable nucleic acid libraries for adenosine receptors
BR112022018176A2 (pt) * 2020-03-13 2022-12-06 Janssen Biotech Inc Materiais e métodos para ligação de siglec-3/cd33
US20210284731A1 (en) * 2020-03-13 2021-09-16 Janssen Biotech, Inc. Methods and materials for modulating an immune response
US20230190810A1 (en) * 2020-03-31 2023-06-22 Fred Hutchinson Cancer Center Anti-cd33 antibodies and uses thereof
US11919944B2 (en) 2020-05-11 2024-03-05 Augmenta Biosciences, Inc. Antibodies for SARS-CoV-2 and uses thereof
JP2023542257A (ja) 2020-09-16 2023-10-05 アムジェン インコーポレイテッド 癌の治療のために二重特異性ｔ細胞誘導分子の治療用量を投与する方法
WO2022159620A1 (en) * 2021-01-21 2022-07-28 Twist Bioscience Corporation Methods and compositions relating to adenosine receptors
EP4294528A2 (en) 2021-02-16 2023-12-27 JANSSEN Pharmaceutica NV Trispecific antibody targeting bcma, gprc5d, and cd3
IL306108A (en) 2021-03-24 2023-11-01 Janssen Biotech Inc Trispecific antibodies targeting CD79b, CD20 and CD3
WO2022228471A1 (zh) * 2021-04-27 2022-11-03 上海驯鹿生物技术有限公司 一种基因编辑的造血干细胞及其与car-t细胞的联合应用
CN117715935A (zh) * 2021-07-30 2024-03-15 南京传奇生物科技有限公司 抗cd33抗体及其用途
CA3228414A1 (en) * 2021-09-02 2023-03-09 Anthony DANIYAN Anti-cd33 antibodies and uses thereof
AU2022344595A1 (en) * 2021-09-13 2024-05-02 Janssen Biotech, Inc CD33 X Vδ2 MULTISPECIFIC ANTIBODIES FOR THE TREATMENT OF CANCER
WO2023081898A1 (en) * 2021-11-08 2023-05-11 Alector Llc Soluble cd33 as a biomarker for anti-cd33 efficacy

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020142000A1 (en) 1999-01-15 2002-10-03 Digan Mary Ellen Anti-CD3 immunotoxins and therapeutic uses therefor
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
HUE026914T2 (en) 2002-11-07 2016-08-29 Immunogen Inc Anti-CD33 antibodies and a method of treating acute myeloid leukemia
CA2577082A1 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
DK3050963T3 (da) 2005-03-31 2019-12-09 Chugai Pharmaceutical Co Ltd Fremgangsmåde til fremstilling af polypeptid ved regulering af arrangement
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
ES2856451T3 (es) 2005-10-11 2021-09-27 Amgen Res Munich Gmbh Composiciones que comprenden anticuerpos específicos para diferentes especies, y usos de las mismas
JP2009541275A (ja) 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー／エス 二重特異性抗体の生産
EP3461842A1 (en) 2007-04-03 2019-04-03 Amgen Research (Munich) GmbH Cross-species-specific binding domain
TR201816277T4 (tr) 2007-04-03 2018-11-21 Amgen Res Munich Gmbh Çapraz-tür-spesifik bağlama alanı.
CA2682626A1 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific bispecific binders
AU2009299794B2 (en) 2008-10-01 2015-08-13 Amgen Research (Munich) Gmbh Cross-species-specific single domain bispecific single chain antibody
RS54900B1 (sr) 2008-10-01 2016-10-31 Amgen Res (Munich) Gmbh Interspecijski specifično psmaxcd3 bispecifično jednolančano antitelo
US9260522B2 (en) 2008-10-01 2016-02-16 Amgen Research (Munich) Gmbh Bispecific single chain antibodies with specificity for high molecular weight target antigens
EP2424567B1 (en) 2009-04-27 2018-11-21 OncoMed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
SG10201800757TA (en) 2010-04-20 2018-02-27 Genmab As Heterodimeric antibody fc-containing proteins and methods for production thereof
UA112062C2 (uk) 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cd33-зв'язувальний агент
PL2635607T3 (pl) 2010-11-05 2020-05-18 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
CA2854233C (en) 2011-11-04 2020-05-12 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
LT2931030T (lt) 2012-12-14 2020-11-10 Open Monoclonal Technology, Inc. Polinukleotidai, koduojantys graužikų antikūnus su žmogaus idiotipais, ir juos apimantys gyvūnai
AR097648A1 (es) 2013-09-13 2016-04-06 Amgen Inc Combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana cd33 y cd3 en el tratamiento de leucemia mieloide
WO2015089344A1 (en) 2013-12-13 2015-06-18 Genentech, Inc. Anti-cd33 antibodies and immunoconjugates
US9212225B1 (en) 2014-07-01 2015-12-15 Amphivena Therapeutics, Inc. Bispecific CD33 and CD3 binding proteins
SG11201701599UA (en) * 2014-09-05 2017-03-30 Janssen Pharmaceutica Nv Cd123 binding agents and uses thereof
CN107922480B (zh) * 2015-06-12 2022-09-23 艾利妥 抗cd33抗体及其使用方法
EP3307779A2 (en) * 2015-06-12 2018-04-18 Alector LLC Anti-cd33 antibodies and methods of use thereof
MA47691A (fr) 2017-08-03 2020-01-08 Alector Llc Anticorps anti-cd33 et leurs procédés d'utilisation
EA202091976A1 (ru) 2018-02-20 2021-07-06 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на cd33, и их применение
MX2020012587A (es) * 2018-05-24 2021-04-28 Janssen Biotech Inc Anticuerpos anti-cd3 y usos de estos.

Also Published As

Publication number Publication date
KR20210013156A (ko) 2021-02-03
CR20200567A (es) 2021-01-20
WO2019224711A3 (en) 2020-01-02
EP3802606A2 (en) 2021-04-14
US20190382481A1 (en) 2019-12-19
MX2020012588A (es) 2021-04-28
IL278844A (en) 2021-01-31
TW202033551A (zh) 2020-09-16
CN112189022A (zh) 2021-01-05
WO2019224711A2 (en) 2019-11-28
MA52771A (fr) 2021-04-14
PE20210180A1 (es) 2021-01-29
CO2020014575A2 (es) 2020-12-10
CL2020003028A1 (es) 2021-04-16
SG11202011210TA (en) 2020-12-30
AU2019274229A1 (en) 2020-11-26
UY38242A (es) 2019-11-29
NI202000088A (es) 2021-03-23
JP2021524244A (ja) 2021-09-13
JOP20190116A1 (ar) 2019-11-24
US11466082B2 (en) 2022-10-11
BR112020023357A2 (pt) 2021-04-27
CA3101270A1 (en) 2019-11-28
PH12020552010A1 (en) 2021-06-14

Similar Documents

Publication Publication Date Title
ECSP20075198A (es) Anticuerpos anti-cd33, anticuerpos biespecíficos anti-cd33/anti-cd3 y usos de estos
CL2019002566A1 (es) Anticuerpos anti-phf-tau y usos de estos.
ECSP18011248A (es) Diacuerpos monovalentes biespecíficos que son capaces de unirse a b7-h3 y cd3, y usos de los mismos
CO2018012374A2 (es) Moléculas de anticuerpo para el tratamiento del cáncer
PH12020552080A1 (en) Dll3-cd3 bispecific antibodies
MX2020009366A (es) Anticuerpos anti-cd73 y usos de los mismos.
CO2019012329A2 (es) Polipéptidos que antagonizan la señalización wnt en células tumorales
PE20170680A1 (es) Tratamientos conjuntos con anticuerpos anti cd40
CL2018002810A1 (es) Anticuerpos anti-factor bb del complemento y usos de estos referencia cruzada.
EA202190807A1 (ru) Антитела к синуклеину
DOP2022000218A (es) Anticuerpos anti-phf-tau y usos de estos
CO2019009815A2 (es) Combinaciones farmacéuticas
EA202092125A1 (ru) Антитела против рецептора фолата 1 и их применения
CL2021001615A1 (es) Anticuerpos anti il-36 y procedimientos de uso de estos
UY39699A (es) Anticuerpos anti-tau y usos de estos
DOP2021000229A (es) Materiales y métodos para modular la inmunidad mediada por cédula t
CO2022006708A2 (es) Anticuerpos trem2 y usos de estos
EA202092122A1 (ru) Антитела против tip-1 и их применения
AR115424A1 (es) Anticuerpos anti-cd33, anticuerpos biespecíficos anti-cd33 / anti-cd3 y usos de estos
EA202092840A1 (ru) Антитела к cd33, биспецифические антитела к cd33/cd3 и их применение
EA202193035A1 (ru) Материалы и способы для модуляции иммунитета, опосредованного т-клетками
UY39698A (es) Anticuerpos humanizados contra el filamento helicoidal emparejado tau y usos de estos
EA202092947A1 (ru) Анти-pvrig/анти-tigit биспецифические антитела и способы их применения
EA202092121A1 (ru) Антитела против cd73 и их применения
AR106442A1 (es) Anticuerpos anti-il2, composiciones y usos